由sindilizumab与局部放射治疗相结合引起的严重免疫媒介性肝炎:一个病例报告
Guofei Ren1, Hangping Chen1, Jing Fang2
1Pharmacy Department, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, Zhejiang, China.
European journal of hospital pharmacy : science and practice
|August 8, 2023
概括
一个罕见的严重免疫媒介性肝炎 (IMH) 病例发生在一个接受辛迪利祖马布治疗和淋巴瘤放射治疗的患者身上. 联合治疗导致致命的肝衰竭,突出显示了潜在的协同毒性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 肝病学 肝病学是一种肝病学.
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 的治疗通常涉及组合疗法.
- 像辛迪利祖马布这样的免疫检查点抑制剂 (ICI) 激活了免疫系统对抗癌症.
- 放射治疗是各种癌症的标准局部治疗方式.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...


